R1	AND Arg1:T3 Arg2:T4	
R2	AND Arg1:T2 Arg2:T4	
R3	Has_value Arg1:T2 Arg2:T5	
R4	Has_value Arg1:T3 Arg2:T5	
R5	multi Arg1:T7 Arg2:T6	
R6	Has_index Arg1:T8 Arg2:T9	
R7	multi Arg1:T12 Arg2:T13	
R8	Has_temporal Arg1:T11 Arg2:T12	
R9	Has_mood Arg1:T11 Arg2:T10	
R10	Has_negation Arg1:T10 Arg2:T14	
R11	Has_temporal Arg1:T7 Arg2:T8	
R12	Has_value Arg1:T19 Arg2:T18	
R13	Has_value Arg1:T20 Arg2:T21	
R14	Subsumes Arg1:T21 Arg2:T22	
T1	Condition 3 16	HIV infection
T2	Measurement 22 28;45 58	plasma concentration
T3	Measurement 33 58	CSF HIV RNA concentration
T4	Procedure 67 87	Roche Amplicor assay
T5	Value 89 107	> 1,000 copies/ mL
T6	Procedure 147 175	antiretroviral therapy (ART)
T7	Condition 143 175	Off antiretroviral therapy (ART)
T8	Temporal 180 206	> 6 weeks before the study
T9	Reference_point 197 206	the study
T10	Mood 214 228	plans to begin
T11	Procedure 229 238	treatment
T12	Temporal 239 261	for the study duration
T13	Reference_point 247 252	study
T14	Negation 211 213	no
T15	Context_Error 229 238	treatment
T16	Non-representable 453 491	Predicted adherence to the medication.
T17	Post-eligibility 496 534	Capable of providing informed consent.
T18	Value 541 549	18 years
T19	Person 550 553	old
T20	Measurement 558 573	CD4 cell counts
T21	Value 574 587	>150 cells/μL
T22	Value 629 642	>250 cells/μL
T23	Not_a_criteria 649 737	When available, subjects will be screened for stability of blood CD4 and HIV RNA levels.
